Since 2012, Mikey Hoag and the Part the Cloud committee and gala, have generated over $17 million in funding for Alzheimer’s research – a remarkable effort that will have a true impact on moving critical studies forward to achieve potential therapies. These awards are designed to accelerate transition of findings from the laboratory, through trials, into possible therapies – filling the gap in Alzheimer’s drug development by providing essential support for early phase clinical studies. Due to this increase in funding, the Alzheimer’s Association has awarded 17 research awards since January 2013. These awards span a variety of targets in Alzheimer’s disease research and fall under the leadership of some of the nation's most prestigious scientists and universities.
Alzheimer's Association continues discussions with potential partners to provide expertise and resources from the pharma industry for PTC awardees and to encourage participants in industry incubator programs to apply to PTC for future program offerings
Featured Grant Recipient: Stephane Cunnane, Ph.D.
Learn more about how Part the Cloud Grant Recipients are selected.
Part the Cloud Challenge on Inflammation Grant Recipients
Isidro Ferrer, M.D., Ph.D.
Bellvitge Biomedical Research Institute
Proposes a Phase II clinical trial to examine if Sativex reduces brain inflammation and helps slow the progression of Alzheimer's disease in people with mild cognitive impairment who may be at an increased risk for developing Alzheimer's.
John M. Olichney, M.D.
University of California, Davis
Proposes a Phase II clinical trial which will examine if the drug Senicapoc reduces brain inflammation and slows or prevents progression of Alzheimer's disease.
Anthony Andrew Oliva, Ph.D.
Proposes a Phase I clinical study of whether (Adult) Mesenchymal Stem Cell Therapy for Neuroinflammation is safe and able to reduce brain inflammation in people with early Alzheimer's disease.
Huntington Potter, Ph.D.
University of Colorado, Denver
Proposes Phase II clinical trial to determine if the FDA-approved cancer drug, Leukine, is able to be repurposed as a safe and effective treatment to slow or prevent the progression of Alzheimer's.
2015 Grant Recipients
Paul A. Newhouse, Vanderbilt University
Title: Phase 1 Testing of a Muscarinic M1 PAM for Alzheimer's Disease
Newhouse and colleagues will test a novel drug,VU0467319, which acts on the muscarinic system in the brain that controls cell-cell communication and nerve cell function. As the first drug of this type to be tested in humans, this study will not only advance a potential therapeutic for Alzheimer's but will also open up the door to this entire class of drugs for future exploration. Learn more.
Mitchel Kling, University of Pennsylvania
Title: A Biomarker-Based Trial of Plasmalogen Repletion in MCI/AD
Kling and colleagues will conduct a Phase 1 clinical study to investigate the man-made lipid, PPI-1011, a type of plasmalogen. This study will not only advance a potential therapeutic for Alzheimer's into Phase 2 but will also advance our understanding of plasmalogen as a marker of biological significance in Alzheimer's. Learn more.
Stephen Cunnane, Ph.D., University of Sherbrooke - Québec, Canada
Title: Proof of Mechanism of a New Ketogenic Supplement Using Dual Tracer PET
This Phase 1b/2a clinical trial will examine the safety and effectiveness of a novel dietary supplement as an alternative fuel source for the brain to stabilize or reverse declining memory observed in early stages of Alzheimer’s disease. The scientists will use advanced brain imaging to determine if the proposed therapy improves brain blood flow, energy use and helps preserve memory function.
Giulio Maria Pasinetti, M.D., Ph.D., Icahn School of Medicine at Mount Sinai - New York, New York
Title: BDPP Treatment for Mild Cognitive Impairment and Prediabetes
This Phase 1b clinical trial will examine the safety and tolerability of a combination treatment using three grape-derived compounds in people with very early stages of Alzheimer’s disease. This novel treatment contains a mixture of polyphenols, which are plant compounds thought to support brain health.
Russell Swerdlow, M.D., University of Kansas Medical Center - Fairway, Kansas
Title: Trial of Oxaloacetate in Alzheimer’s Disease (TOAD) Study
This Phase 1b clinical trial will examine the safety and effectiveness of oxaloacetate as an alternative energy source to improve brain function in individuals with Alzheimer’s disease. Providing the brain an alternative fuel source may help slow or prevent brain changes associated with the disease process.
Update: Dr. Russell Swerdlow, PTC 2015 awardee, discusses possible biological pathways important for Alzheimer’s disease in recent PRI interview
Tim West, Ph.D., C2N Diagnostics - St. Louis, Missouri
Title: A Single Ascending-Dose, Double-Blinded, Placebo-Controlled Study of an Anti-Tau Antibody
This Phase 1 clinical trial will examine the safety and effectiveness of an antibody against tau to treat various dementias, including Progressive Supranuclear Palsy (PSP) and Alzheimer’s disease. The results will inform future clinical trials designed to determine if the antibody removes tau from the human brain and results in improved cognitive function.
Update: PTC 2015 awardee C2N Diagnostics partners with AbbVie for advancing tau antibodies in clinical trials for Alzheimer’s disease and Progressive Superior Palsy (PSP)
Whitney Wharton, Ph.D., Emory University - Atlanta, Georgia
Title: Mechanistic Potential of Antihypertensives in Preclinical Alzheimer’s
This Phase 1b clinical trial will determine if the FDA-approved antihypertensive drug, perindopril, may work by mechanisms other than lowering blood pressure to ultimately reduce Alzheimer’s risk in African-Americans with a family history of Alzheimer’s disease.
2013 Grant Recipients
Adam L. Boxer, M.D, Ph.D., University of California, San Francisco
Title: Phase I Multiple Ascending Dose Trial of the MT Stabilizer TPI-287 for AD
Dr. Boxer and his team are working to moderate the stability of microtubules — small, tube-like structures that act like a skeleton inside cells, maintain cell structure and help to transport nutrients throughout the cell —potentially decreasing the abnormal buildup of tau protein into tangles, one of the hallmark brain changes of Alzheimer’s disease.
Update: UCSF team – led by Adam Boxer - launched the safety clinical study with TPI-287. Further, Dr. Boxer received a significant award to establish a clinical research team to study loss of brain cell function in dementias.
Dr. Adam Boxer is highlighted as part of the international tau partnership supported by Richard Rainwater.
Frank Longo, M.D., Stanford University and Anne Longo, Pharmatrophix, Inc.
Title: Phase I Trial for P75 Receptor Ligand
This study aims to test a therapy that targets the cell death pathway associated with Alzheimer’s disease by inhibiting a known component. The researchers hope to ultimately determine whether this decreases the detrimental effects of Alzheimer’s in the brain.
Update: Dr. Frank Longo and his group at Pharmatrophix are gearing up to launch their next clinical study thanks to the success of their initial safety study, partially funded by PTC.
Dr. Frank Longo, PTC 2013 recipient, is part of team investigating underlying biology of why stroke may be a risk factor for dementia.
Ahmad Salehi, M.D., Ph.D., Palo Alto Institute for Research & Education, Inc.
Title: Improving ß2 Adrenergic Signaling in Alzheimer’s Disease
Researchers at the Palo Alto Institute for Research & Education, Inc., are exploring potential therapeutics to improve the health of brain connections thought to play an early role in the disease processes.
Dale E. Bredesen, M.D., Buck Institute for Research on Aging
Title: An Exploratory Safety, PK/PD, and Preliminary Efficacy Study of F03 in MCI
This study strives to impact the activity level of Amyloid Precursor Protein (APP), the complex responsible for the production of the beta amyloid — thereby potentially influencing the amount of beta amyloid produced in the brain.
Update: Part the Cloud awardee Dr. Dale Bredesen published a report on 10 individuals who saw reversal of cognition issues following a personalized lifestyle-intervention.
Keith Vossel, M.D., University of California, San Francisco and Gladstone Institute for Neurological Disease
Title: Phase 2a Levetiracetam Trial for AD-Associated Network Hyperexcitability
Led by Dr. Keith Vossel, these scientists are working to moderate the amount of underlying electrical activity of the brain cells associated with Alzheimer’s disease to potentially impact the rate an individuals’ cognition declines.
Mike Weiner, MD., University of California, San Francisco
The Part the Cloud initiative also supported, in part, Mike Weiner, MD (principal investigator of ADNI) and the Whole Genome Sequencing Alzheimer’s Disease Neuroimaging Initiative (WGS-ADNI), a project to sequence the whole genome of more than 800 individuals. The genome data will be available to researchers around the world this summer, enabling further study of the genes related to Alzheimer’s.
Update: The competitive renewal of the Alzheimer’s Disease Neuroimaging Initiative (ADNI), where Mike Weiner, MD serves as principal investigator, got a very good score after review at the National Institutes of Health (NIH) and will be funded for 5 more years, making it the largest funded program on Alzheimer’s in the United States.